Blood cancers

Extension for blinatumomab PBS listing

The PBS listing of blinatumomab (Blincyto) is being extended from 1 December to include treatment of patients with acute lymphoblastic leukaemia and minimal residual disease (MRD). The listing follows a recommendation from the Pharmaceutical Benefits Advisory Committee (PBAC) in May 2019 to extend the listing for people with B-cell precursor (ALL) in haematological complete remission ...

Already a member?

Login to keep reading.

© 2021 the limbic